The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy

Abstract

BackgroundThis study aimed to preliminarily assess the relationship between erythropoietin‐producing hepatocellular carcinoma receptor A3 (EphA3) and androgen receptor (AR) protein expression levels and prognosis in prostate cancer (PCa) to better understand the role of EphA3 in the prognosis and progression of PCa.MaterialsWe investigated the expression of EphA3 and AR in human PCa by immunohistochemistry.ResultsEphA3 and AR were both significantly upregulated in PCa, with expression mainly localized to the nucleus. A high level of AR expression was found in 48.4% of 64 tumor samples, which was significantly more than in the adjacent tissue samples (15.6%) (P < 0.01). The percentage of samples expressing a high level of EphA3 was significantly greater in the PCa samples (54.7%) than in the adjacent tissue samples (20.3%) for the 64 tumors (P < 0.01). The high levels of EphA3 and AR expression in the PCa tissue samples were both correlated with the pathological stage, bladder and rectal invasion, distant metastasis, and preoperative PSA level (both P < 0.05). The survival time was significantly shorter in high levels of AR expression of patients. (P < 0.01). A high level of EphA3 in PCa patients suggests a poor prognosis (P < 0.05). Biochemical recurrence, distant metastasis, and the final scores of EphA3 and AR expression were significantly correlated with the prognosis of PCa (P < 0.05).ConclusionsIncreased EphA3 expression is an independent prognostic factor for a poor outcome and decreased survival in PCa.

Identification of Core Prognosis-Related Candidate Genes in Cervical Cancer via Integrated Bioinformatical Analysis

“…Androgen receptor (AR) acts as an androgen-activated transcription factor that regulates eukaryotic gene expression and affects cellular proliferation and differentiation in a wide variety of human adult tissues, including male and female reproductive tissues [19]. A growing amount of literature has demonstrated that AR overexpression is positively correlated with cancer progression and poor prognosis in prostate cancer [20,21] and colorectal cancer [22]. However, the role of expression alterations of AR in relation to cervical cancer is not well understood.…”

EPHA3 Contributes to Epigenetic Suppression of PTEN in Radioresistant Head and Neck Cancer

“…EPHA3 is overexpressed in various cancers, such as glioblastoma, gastric cancer, and prostate cancer, and has an important role in tumorigenesis, aggressiveness, and radioresistance [15][16][17][18][19]. Some contradictory results underline the complexity of Eph receptor biology in cancer settings, and EPHA3 does not play a major role in lung and colorectal tumorigenesis [20,21].…”

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer

“…Ephrin receptor EPHA3 expression has been associated with tumorigenicity in vitro [36] and has been shown to be an independent prognostic indicator of poor survival [37].…”

“…Ephrin receptor EPHA3 expression has been associated with tumorigenicity in vitro [ 36 ] and has been shown to be an independent prognostic indicator of poor survival [ 37 ]. The apparent role of EPHA3 in our study as a negative predictor of hormonal therapy response requires further investigation.…”